FDA Shakeup: Marty Makary's Resignation Sparks Controversy

U.S. FDA Commissioner Marty Makary has resigned amid tensions with the White House and health advisers, particularly regarding controversial decisions on flavored vapes. His resignation follows pressure from Republican leaders and anti-abortion groups. Deputy Commissioner Kyle Diamantas will serve as acting head while the search for a permanent replacement continues.

FDA Commissioner Marty Makary has stepped down after weeks of discord with President Donald Trump and other top White House and health officials. His tenure faced intense scrutiny over controversial FDA decisions, including the handling of flavored vapes and contentious drug approvals.

Makary's departure comes amid mounting pressure from Republican leaders and influential groups, who critiqued his approach to key health policies. In a move to address the leadership gap, Deputy Commissioner Kyle Diamantas will assume the role temporarily as the administration seeks a permanent candidate.

The White House has expressed its intent to find more traditional candidates for health leadership roles, while Makary's resignation sheds light on the complex political dynamics within health policy-making in the U.S.